Descrizione

According to a report by StrategyHelix, the global high content screening market is set to increase by US$ 839.4 milioni durante 2022-2028, growing at a CAGR of 9.2% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for high content screening. The global high content screening market is segmented on the basis of component, applicazione, end user, e regione. On the basis of component, the global high content screening market has been segmented into consumables (reagents and kits), instrument or platform, servizi, software and analytics. The instrument or platform segment held the largest revenue share in 2021. Per applicazione, the global high content screening market has been segmented into compound profiling, drug discovery, molecular diagnosis, oncology, toxicity studies, altri. Tra questi, the drug discovery segment was accounted for the highest revenue generator in 2021. Based on end user, the global high content screening market is categorized into academic institutions, laboratories and pathology centers, pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment captured the largest share of the market in 2021. Geograficamente, the global high content screening market is segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The instrument market is further segmented into cytometers, detectors and sensors, imaging devices, liquid handling instruments, plate readers, e altri. Globally, the imaging devices segment made up the largest share of the high content screening market.

The global high content screening market is highly competitive. The prominent players operating in the global high content screening market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corp., GE Healthcare, Merck KGaA, Olympus Corporation, PerkinElmer Inc., Sartorius AG, Thermo Fisher Scientific Inc., Yokogawa Electric Corporation.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the high content screening market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Component: consumables (reagents and kits), instrument or platform, servizi, software and analytics
Applicazione: compound profiling, drug discovery, molecular diagnosis, oncology, toxicity studies, altri
Utente finale: academic institutions, laboratories and pathology centers, pharmaceutical and biotechnology companies
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global high content screening market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. High content screening market overview
Parte 3. Market breakdown by component
– Consumables (reagents and kits)
– Instrument or platform
– Servizi
– Software and analytics
Parte 4. Market breakdown by application
– Compound profiling
– Drug discovery
– Molecular diagnosis
– Oncology
– Toxicity studies
– Altri
Parte 5. Market breakdown by end user
– Academic institutions
– Laboratories and pathology centers
– Pharmaceutical and biotechnology companies
Parte 6. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 7. Aziende chiave
– Agilent Technologies Inc.
– Bio-Rad Laboratories, Inc.
– Danaher Corp.
– GE Healthcare
– Merck KGaA
– Olympus Corporation
– PerkinElmer, Inc.
– Sartorius AG
– Thermo Fisher Scientific Inc.
– Yokogawa Electric Corporation
Informazioni su StrategyHelix
Disclaimer